KNa1.1 gain-of-function preferentially dampens excitability of murine parvalbumin-positive interneurons

Tracy S. Gertler*, Suraj Cherian, Jean Marc DeKeyser, Jennifer A. Kearney, Alfred L. George

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

KCNT1 encodes the sodium-activated potassium channel KNa1.1, expressed preferentially in the frontal cortex, hippocampus, cerebellum, and brainstem. Pathogenic missense variants in KCNT1 are associated with intractable epilepsy, namely epilepsy of infancy with migrating focal seizures (EIMFS), and sleep-related hypermotor epilepsy (SHE). In vitro studies of pathogenic KCNT1 variants support predominantly a gain-of-function molecular mechanism, but how these variants behave in a neuron or ultimately drive formation of an epileptogenic circuit is an important and timely question. Using CRISPR/Cas9 gene editing, we introduced a gain-of-function variant into the endogenous mouse Kcnt1 gene. Compared to wild-type (WT) littermates, heterozygous and homozygous knock-in mice displayed greater seizure susceptibility to the chemoconvulsants kainate and pentylenetetrazole (PTZ), but not to flurothyl. Using acute slice electrophysiology in heterozygous and homozygous Kcnt1 knock-in and WT littermates, we demonstrated that CA1 hippocampal pyramidal neurons exhibit greater amplitude of miniature inhibitory postsynaptic currents in mutant mice with no difference in frequency, suggesting greater inhibitory tone associated with the Kcnt1 mutation. To address alterations in GABAergic signaling, we bred Kcnt1 knock-in mice to a parvalbumin-tdTomato reporter line, and found that parvalbumin-expressing (PV+) interneurons failed to fire repetitively with large amplitude current injections and were more prone to depolarization block. These alterations in firing can be recapitulated by direct application of the KNa1.1 channel activator loxapine in WT but are occluded in knock-in littermates, supporting a direct channel gain-of-function mechanism. Taken together, these results suggest that KNa1.1 gain-of-function dampens interneuron excitability to a greater extent than it impacts pyramidal neuron excitability, driving seizure susceptibility in a mouse model of KCNT1-associated epilepsy.

Original languageEnglish (US)
Article number105713
JournalNeurobiology of Disease
Volume168
DOIs
StatePublished - Jun 15 2022

Funding

T.S.G. received consulting fees from Biogen. J.A.K. received research funding from Pfizer, Praxis, Ovid and Takeda, received consulting fees from Neurocycle Therapeutics, and received royalty income from GW Pharmaceuticals, Novartis, Stoke Therapeutics, StrideBio, Pfizer, Lundbeck, Bright Minds Biosciences, Xenon Pharmaceuticals, Noema Pharma, and Encoded Genomics. A.L.G. received research funding from Tevard Biosciences and Praxis Precision Medicines, and received consulting fees from Neurocrine Biosciences. This work was supported by NIH grants NS104237 (TSG) and NS108874 (ALG, JAK), a research grant from the Child Neurology Foundation and Pediatric Epilepsy Research Foundation (TSG), a gift from the Davee Foundation (ALG), and the Northwestern Transgenic and Targeted Mutagenesis Laboratory .

Keywords

  • Epilepsy
  • Interneuron
  • KCNT1
  • Mouse
  • Potassium channel

ASJC Scopus subject areas

  • Neurology

Fingerprint

Dive into the research topics of 'KNa1.1 gain-of-function preferentially dampens excitability of murine parvalbumin-positive interneurons'. Together they form a unique fingerprint.

Cite this